Stock Market Reviews

FENC (Fennec Pharmaceuticals Inc.) News

Get the latest news, insights, and market updates on FENC (Fennec Pharmaceuticals Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More
  Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the “buy the rumor, sell the news” cliche came in fast and strong, quickly turning the rally into ... Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More
  Feb 12, 2026 - $FENC
• Positive Signs As Multiple Insiders Buy Fennec Pharmaceuticals Stock
  When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
  Jan 6, 2026 - $FENC
• Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
  NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis). The Common Shares were so
  Dec 26, 2025 - $FENC
• Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
  – City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Receiving Cisplatin-Based Chemotherapy – RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the planned initiation of an investigator-sp
  Dec 9, 2025 - $FENC
• Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint
  Fennec Pharmaceuticals (FENC) said Tuesday a phase 2/3 trial of Pedmark, its sodium thiosulfate inje
  Dec 2, 2025 - $FENC
• Fennec Pharmaceuticals Reports Positive Top-line Results From Japan Trial
  Fennec Pharmaceuticals (FRX.TO) up near 5% in pre-market trading, Tuesday announced positive topline
  Dec 2, 2025 - $FENC
• Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
  – Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – – PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate – – The Company Plans to Pursue Registration and is Exploring Partnering or Licensi
  Dec 2, 2025 - $FENC
• Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
  RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast. Webcast Detail: Date:Wednesday, December 3, 2025Time:1:00 p.m. Eastern TimeWebcast Link:https://event.webcasts.com/starthere.jsp?ei
  Nov 26, 2025 - $FENC
• Loss-Making Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Expected To Breakeven In The Medium-Term
  With the business potentially at an important milestone, we thought we'd take a closer look at Fennec Pharmaceuticals...
  Nov 25, 2025 - $FENC
• Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
  RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company’s previously announced underwritten public offering in the United States and concur
  Nov 19, 2025 - $FENC